<code id='03C0D6A715'></code><style id='03C0D6A715'></style>
    • <acronym id='03C0D6A715'></acronym>
      <center id='03C0D6A715'><center id='03C0D6A715'><tfoot id='03C0D6A715'></tfoot></center><abbr id='03C0D6A715'><dir id='03C0D6A715'><tfoot id='03C0D6A715'></tfoot><noframes id='03C0D6A715'>

    • <optgroup id='03C0D6A715'><strike id='03C0D6A715'><sup id='03C0D6A715'></sup></strike><code id='03C0D6A715'></code></optgroup>
        1. <b id='03C0D6A715'><label id='03C0D6A715'><select id='03C0D6A715'><dt id='03C0D6A715'><span id='03C0D6A715'></span></dt></select></label></b><u id='03C0D6A715'></u>
          <i id='03C0D6A715'><strike id='03C0D6A715'><tt id='03C0D6A715'><pre id='03C0D6A715'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:8542
          Medicare and money photo illustration.
          Adobe

          Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier. 

          CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

          advertisement

          “I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more
          What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise
          What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

          MollyFerguson/STATHello!SometakesandthoughtsonGilead’sTrodelvytroubles,ElevationOncology’ssurprising

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Parkinson’s finding may lead to tests and, someday, treatments

          CourtesyMarkSeligerNEWYORK— MichaelJ.FoxwassittinginhisUpperEastSideofficesurroundedbyEmmysandanOsca